Poolbeg Pharma PLC (POLB.L)
LSE · GBp · Healthcare · Biotechnology
£6.70 (-0.74%) as of
Key statistics
- Market cap
- 51.15M
- Forward P/E
- -11.36
- EPS (TTM)
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- 3.30 – 9.30
- Beta
- 1.84
- Profit margin
- 0.00%
- Analyst target
- £19.00
- Volume
- 764.62k
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- London, United Kingdom
- Employees
- 15
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.